Eplerenone for the treatment of cardiovascular disorders

Masataka Watanabe, Henry Krum

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


The clinical utility and ultimately guideline recommendations for aldosterone receptor-blocking agents in cardiovascular disorders is clearly mentioned by a number of major clinical outcome trials. This article reviews the pharmacology, clinical efficacy and safety of the two currently available receptor blocking agents: spironolactone and eplerenone. The potential utility of eplerenone and other mineralocorticoid receptor agents beyond current clinical indications will also be examined.
Original languageEnglish
Pages (from-to)831 - 838
Number of pages8
JournalExpert Review of Cardiovascular Therapy
Issue number7
Publication statusPublished - 2012

Cite this